Type 2 & other diabetes

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Diabetes CarePublished Prespecified analysis of the DAPA-CKD randomised trial

Authors' conclusion

Dapagliflozin reduced kidney and cardiovascular events in patients with type 2 diabetes and CKD across baseline GLT class or classes in combination.

Study context

Population
Adults with estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio 200–5,000 mg/g; analysis in T2D and chronic kidney disease (CKD) by baseline glucose-lowering therapy (GLT) class or number of GLTs2,906 with T2D
Participants
4,304 adults
Comparison
Dapagliflozin 10 mg vs placebo once daily, by baseline glucose-lowering therapy (GLT)
Primary endpoint
Composite of:
  • ≥50% eGFR decline
  • End-stage kidney disease
  • Kidney or cardiovascular death
Methodological detailsprespecified subgroup analysis, placebo-controlled
  • Prespecified subgroup analysis
  • Placebo-controlled

Primary result

As reported in the abstract

Primary composite outcome:
  • By baseline GLT class
  • Number of GLTs
  • Effects of dapagliflozin on the primary composite outcome consistent across GLT classes and number of GLTs
  • Dapagliflozin vs Placebo: all interaction P > 0.08

Secondary outcomes

OutcomeHR (95% CI)P value
Initiation of insulin therapy during follow-up0.72 (0.54–0.96)P = 0.025

Secondary end points (kidney composite, cardiovascular composite, all-cause mortality) by GLT class or number

Consistent benefit of dapagliflozin vs placebo regardless of background GLT class or number of GLTs

Rate of eGFR decline by GLT class or number

Consistent effect of dapagliflozin regardless of background GLT

Safety

Safety end points consistent regardless of background GLT class or number of GLTs

Original publication

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. Diabetes Care. Published 20 January 2023. doi:10.2337/dc22-1514

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.